Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Cancer Gene Ther. 2015 Aug 14;22(9):438–444. doi: 10.1038/cgt.2015.36

Fig. 3.

Fig. 3

Anti-tumor effect of alisertib/MV-s-NAP combination treatment against breast cancer cells. MCF-7 cells were treated with 70 nM alisertib (corresponding to the IC50) and infected with MV-s-NAP at MOI of 0.1 (A) or 1 (B). The cytotoxic effect of alisertib/MV-s-NAP combination on MDA231-lu-P4 cells was evaluated following treatment with 200 nM alisertib (corresponding to the IC50 for this cell line) and infected with MV-s-NAP at MOI of 0.1 (C) or 1 (D). Cell viability at different time points was measured by MTT assay. MLN = alisertib